Tilray Stock Could Shoot 40% Higher, Says Wall Street

78
4
Favorite

Tilray Stock Could Shoot 40% Higher, Says Wall Street

TheStreet2021-09-20

Wall Street’s consensus on TLRY suggests that shares of the cannabis company have sizable upside potential. Wall Street Memes looks at the bullish case on Tilray stock. Canadian-based drug ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（4）

IamZhong
·2021-09-22
Rubbish
Reply
2
Report
Jason1205
·2021-09-20
How can I believe in it?
Reply
Like
Report
卖女孩的小火柴v
·2021-09-20
Ok
Reply
4
Report
NRN
·2021-09-20
?
Reply
4
Report
Fold Replies
- KBchan:
  moon
  2021-09-20
  Reply
  Report
- 卖女孩的小火柴v:
  Ok
  2021-09-20
  Reply
  Report
- Pschoa:
  Hi
  2021-09-20
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1159389843?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-09-20 08:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159389843","market":"us","top_or_hot":-1,"title":"Tilray Stock Could Shoot 40% Higher, Says Wall Street","media":"TheStreet","content":"<div>\n<p>Wall Street’s consensus on TLRY suggests that shares of the cannabis company have sizable upside potential. Wall Street Memes looks at the bullish case on Tilray stock.\nCanadian-based drug ...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/tilray-stock-could-shoot-40-higher-says-wall-street\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Stock Could Shoot 40% Higher, Says Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Stock Could Shoot 40% Higher, Says Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-20 08:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/other-memes/tilray-stock-could-shoot-40-higher-says-wall-street><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street’s consensus on TLRY suggests that shares of the cannabis company have sizable upside potential. Wall Street Memes looks at the bullish case on Tilray stock.\nCanadian-based drug ...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/tilray-stock-could-shoot-40-higher-says-wall-street\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLRY","symbol_name":"Tilray Inc.","start_time":0,"source_url":"https://www.thestreet.com/memestocks/other-memes/tilray-stock-could-shoot-40-higher-says-wall-street","article_id":"1159389843","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159389843","pubTimestamp":1632096090,"sourceInfo":null,"weMediaInfo":null,"summary":"Wall Street’s consensus on TLRY suggests that shares of the cannabis company have sizable upside pot","collect":0,"end_time":0,"defaultTopTitle":"thestreet.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TLRY":"Tilray Inc."},"translate_title":"华尔街称，Tilray的股价可能会上涨40%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLRY":0.9},"content_text":"Wall Street’s consensus on TLRY suggests that shares of the cannabis company have sizable upside potential. Wall Street Memes looks at the bullish case on Tilray stock.\nCanadian-based drug manufacturer Tilray is one of the most popular cannabis stocks across the online forums. Shares have sunk around 80% to $12 since spiking in early February, catching the attention of bargain hunters.\nFigure 1: Tilray products are displayed in Nanaimo.\nFollowing dismal performance in the past months, Wall Street sees opportunity. Could now be a good time to buy the stock near its 2021 lows?\nThe consensus rating on Tilray stock is a moderate buy with solid 40% upside potential. Based on the average of 11 reports published in the last 3 months, TLRY should be worth just short of $17.\nThe most bullish analyst is Jefferies’ Owen Bennett, who sees gain potential of 125% at his price target of $27. He expects Tilray to strike sizable deals in the US some time soon. The analyst also thinks that Tilray should buy cannabis assets to achieve the company’s ambitious sales target.\nOnly a bit less bullish is Bank of America’s analyst Heather Balsky. Shebelievesin 80% upside at a price target of $21.50. The acquisition of MedMen positions the company well in the US and provides distribution opportunities in Canada and Europe. The analyst stated:\n\n“We expect Tilray to pursue additional opportunities in the US with a focus on brands versus acquiring certain licenses. We view each incremental transaction in the US cannabis market as a positive catalyst.\"\n\nNot so bullish was the latest take from Piper Sandler. Analyst Michael Lavery reiterated his neutral position on TLRY stock and lowered his price target from $15 to $14.\nAccording to him, increased competition from low-price providers should weigh on Tilray. Still, despite his neutral stance, the analyst sees 19% upside on TLRY over the next year – not bad, considering how richly valued stocks in general have become in the past several months.\nThe least bullish analyst on record is CIBC John Zamparo, whoseta price target of $13.40 on TLRY two months ago. The analyst believes that forecasting the cannabis industry is very difficult – more so for Tilray, after its reverse-merger deal with Aphria earlier in 2021.\nWall Street Meme’s take\n“Regulation” is still the key word for cannabis stocks. Lack of positive news regarding legalization can lead to extended periods of softness in stock prices, which has been happening lately. However, Wall Street appears to see more upside than downside in the space.\nTilray faces the usual integration risks following the recent Aphria and MedMen deals. Still, this may be what it takes for the company to position itself ahead of the competition. As the cannabis industry matures, Tilray may emerge as a winner, and its stock could ride the upside.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":869186883,"gmtCreate":1632267171342,"gmtModify":1676530737243,"author":{"id":"3573377839632850","authorId":"3573377839632850","name":"IamZhong","avatar":"https://static.tigerbbs.com/3e52a0b5ff1390e09fa1d349bc20337b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573377839632850","authorIdStr":"3573377839632850"},"htmlText":"Rubbish","listText":"Rubbish","text":"Rubbish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869186883","repostId":1159389843,"repostType":2,"repost":{"id":"1159389843","pubTimestamp":1632096090,"share":"https://ttm.financial/m/news/1159389843?lang=&edition=fundamental","pubTime":"2021-09-20 08:01","market":"us","language":"en","title":"Tilray Stock Could Shoot 40% Higher, Says Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1159389843","media":"TheStreet","summary":"Wall Street’s consensus on TLRY suggests that shares of the cannabis company have sizable upside pot","content":"<p>Wall Street’s consensus on TLRY suggests that shares of the cannabis company have sizable upside potential. Wall Street Memes looks at the bullish case on Tilray stock.</p>\n<p>Canadian-based drug manufacturer Tilray&nbsp;is one of the most popular cannabis stocks across the online forums. Shares have sunk around 80% to $12 since spiking in early February, catching the attention of bargain hunters.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3186cce4e6eba2601c4b1943a3d82a72\" tg-width=\"804\" tg-height=\"536\" width=\"100%\" height=\"auto\"><span>Figure 1: Tilray products are displayed in Nanaimo.</span></p>\n<p>Following dismal performance in the past months, Wall Street sees opportunity. Could now be a good time to buy the stock near its 2021 lows?</p>\n<p>The consensus rating on Tilray stock is a&nbsp;moderate buy&nbsp;with solid 40% upside potential. Based on the average of 11 reports published in the last 3 months, TLRY should be worth just short of $17.</p>\n<p>The most bullish analyst is&nbsp;<b>Jefferies</b>’ Owen Bennett, who sees gain potential of 125% at his price target of $27. He&nbsp;expects&nbsp;Tilray to strike sizable deals in the US some time soon. The analyst also thinks that Tilray should buy cannabis assets to achieve the company’s ambitious sales target.</p>\n<p>Only a bit less bullish is&nbsp;<b>Bank of America</b>’s analyst Heather Balsky. Shebelievesin 80% upside at a price target of $21.50. The acquisition of MedMen positions the company well in the US and provides distribution opportunities in Canada and Europe. The analyst stated:</p>\n<blockquote>\n <i>“We expect Tilray to pursue additional opportunities in the US with a focus on brands versus acquiring certain licenses. We view each incremental transaction in the US cannabis market as a positive catalyst.\"</i>\n</blockquote>\n<p>Not so bullish was the latest take from&nbsp;<b>Piper Sandler</b>. Analyst Michael Lavery reiterated his neutral position on TLRY stock and lowered his price target from $15 to $14.</p>\n<p>According&nbsp;to him, increased competition from low-price providers should weigh on Tilray. Still, despite his neutral stance, the analyst sees 19% upside on TLRY over the next year – not bad, considering how richly valued stocks in general have become in the past several months.</p>\n<p>The least bullish analyst on record is&nbsp;<b>CIBC</b>&nbsp;John Zamparo, whoseta price target of $13.40 on TLRY two months ago. The analyst believes that forecasting the cannabis industry is very difficult – more so for Tilray, after its reverse-merger deal with Aphria earlier in 2021.</p>\n<p><b>Wall Street Meme’s take</b></p>\n<p>“Regulation” is still the key word for cannabis stocks. Lack of positive news regarding legalization can lead to extended periods of softness in stock prices, which has been happening lately. However, Wall Street appears to see more upside than downside in the space.</p>\n<p>Tilray faces the usual integration risks following the recent Aphria and MedMen deals. Still, this may be what it takes for the company to position itself ahead of the competition. As the cannabis industry matures, Tilray may emerge as a winner, and its stock could ride the upside.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Stock Could Shoot 40% Higher, Says Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Stock Could Shoot 40% Higher, Says Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-20 08:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/other-memes/tilray-stock-could-shoot-40-higher-says-wall-street><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street’s consensus on TLRY suggests that shares of the cannabis company have sizable upside potential. Wall Street Memes looks at the bullish case on Tilray stock.\nCanadian-based drug ...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/tilray-stock-could-shoot-40-higher-says-wall-street\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://www.thestreet.com/memestocks/other-memes/tilray-stock-could-shoot-40-higher-says-wall-street","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159389843","content_text":"Wall Street’s consensus on TLRY suggests that shares of the cannabis company have sizable upside potential. Wall Street Memes looks at the bullish case on Tilray stock.\nCanadian-based drug manufacturer Tilray is one of the most popular cannabis stocks across the online forums. Shares have sunk around 80% to $12 since spiking in early February, catching the attention of bargain hunters.\nFigure 1: Tilray products are displayed in Nanaimo.\nFollowing dismal performance in the past months, Wall Street sees opportunity. Could now be a good time to buy the stock near its 2021 lows?\nThe consensus rating on Tilray stock is a moderate buy with solid 40% upside potential. Based on the average of 11 reports published in the last 3 months, TLRY should be worth just short of $17.\nThe most bullish analyst is Jefferies’ Owen Bennett, who sees gain potential of 125% at his price target of $27. He expects Tilray to strike sizable deals in the US some time soon. The analyst also thinks that Tilray should buy cannabis assets to achieve the company’s ambitious sales target.\nOnly a bit less bullish is Bank of America’s analyst Heather Balsky. Shebelievesin 80% upside at a price target of $21.50. The acquisition of MedMen positions the company well in the US and provides distribution opportunities in Canada and Europe. The analyst stated:\n\n“We expect Tilray to pursue additional opportunities in the US with a focus on brands versus acquiring certain licenses. We view each incremental transaction in the US cannabis market as a positive catalyst.\"\n\nNot so bullish was the latest take from Piper Sandler. Analyst Michael Lavery reiterated his neutral position on TLRY stock and lowered his price target from $15 to $14.\nAccording to him, increased competition from low-price providers should weigh on Tilray. Still, despite his neutral stance, the analyst sees 19% upside on TLRY over the next year – not bad, considering how richly valued stocks in general have become in the past several months.\nThe least bullish analyst on record is CIBC John Zamparo, whoseta price target of $13.40 on TLRY two months ago. The analyst believes that forecasting the cannabis industry is very difficult – more so for Tilray, after its reverse-merger deal with Aphria earlier in 2021.\nWall Street Meme’s take\n“Regulation” is still the key word for cannabis stocks. Lack of positive news regarding legalization can lead to extended periods of softness in stock prices, which has been happening lately. However, Wall Street appears to see more upside than downside in the space.\nTilray faces the usual integration risks following the recent Aphria and MedMen deals. Still, this may be what it takes for the company to position itself ahead of the competition. As the cannabis industry matures, Tilray may emerge as a winner, and its stock could ride the upside.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":860175742,"gmtCreate":1632149107086,"gmtModify":1676530711836,"author":{"id":"262190804341046","authorId":"262190804341046","name":"Jason1205","avatar":"https://static.tigerbbs.com/a22c3af3bb938bf74c151660df1d68dd","vip":1,"crmLevel":9,"crmLevelSwitch":0,"idStr":"262190804341046","authorIdStr":"262190804341046"},"htmlText":"How can I believe in it?","listText":"How can I believe in it?","text":"How can I believe in it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/860175742","repostId":1159389843,"repostType":2,"repost":{"id":"1159389843","pubTimestamp":1632096090,"share":"https://ttm.financial/m/news/1159389843?lang=&edition=fundamental","pubTime":"2021-09-20 08:01","market":"us","language":"en","title":"Tilray Stock Could Shoot 40% Higher, Says Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1159389843","media":"TheStreet","summary":"Wall Street’s consensus on TLRY suggests that shares of the cannabis company have sizable upside pot","content":"<p>Wall Street’s consensus on TLRY suggests that shares of the cannabis company have sizable upside potential. Wall Street Memes looks at the bullish case on Tilray stock.</p>\n<p>Canadian-based drug manufacturer Tilray&nbsp;is one of the most popular cannabis stocks across the online forums. Shares have sunk around 80% to $12 since spiking in early February, catching the attention of bargain hunters.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3186cce4e6eba2601c4b1943a3d82a72\" tg-width=\"804\" tg-height=\"536\" width=\"100%\" height=\"auto\"><span>Figure 1: Tilray products are displayed in Nanaimo.</span></p>\n<p>Following dismal performance in the past months, Wall Street sees opportunity. Could now be a good time to buy the stock near its 2021 lows?</p>\n<p>The consensus rating on Tilray stock is a&nbsp;moderate buy&nbsp;with solid 40% upside potential. Based on the average of 11 reports published in the last 3 months, TLRY should be worth just short of $17.</p>\n<p>The most bullish analyst is&nbsp;<b>Jefferies</b>’ Owen Bennett, who sees gain potential of 125% at his price target of $27. He&nbsp;expects&nbsp;Tilray to strike sizable deals in the US some time soon. The analyst also thinks that Tilray should buy cannabis assets to achieve the company’s ambitious sales target.</p>\n<p>Only a bit less bullish is&nbsp;<b>Bank of America</b>’s analyst Heather Balsky. Shebelievesin 80% upside at a price target of $21.50. The acquisition of MedMen positions the company well in the US and provides distribution opportunities in Canada and Europe. The analyst stated:</p>\n<blockquote>\n <i>“We expect Tilray to pursue additional opportunities in the US with a focus on brands versus acquiring certain licenses. We view each incremental transaction in the US cannabis market as a positive catalyst.\"</i>\n</blockquote>\n<p>Not so bullish was the latest take from&nbsp;<b>Piper Sandler</b>. Analyst Michael Lavery reiterated his neutral position on TLRY stock and lowered his price target from $15 to $14.</p>\n<p>According&nbsp;to him, increased competition from low-price providers should weigh on Tilray. Still, despite his neutral stance, the analyst sees 19% upside on TLRY over the next year – not bad, considering how richly valued stocks in general have become in the past several months.</p>\n<p>The least bullish analyst on record is&nbsp;<b>CIBC</b>&nbsp;John Zamparo, whoseta price target of $13.40 on TLRY two months ago. The analyst believes that forecasting the cannabis industry is very difficult – more so for Tilray, after its reverse-merger deal with Aphria earlier in 2021.</p>\n<p><b>Wall Street Meme’s take</b></p>\n<p>“Regulation” is still the key word for cannabis stocks. Lack of positive news regarding legalization can lead to extended periods of softness in stock prices, which has been happening lately. However, Wall Street appears to see more upside than downside in the space.</p>\n<p>Tilray faces the usual integration risks following the recent Aphria and MedMen deals. Still, this may be what it takes for the company to position itself ahead of the competition. As the cannabis industry matures, Tilray may emerge as a winner, and its stock could ride the upside.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Stock Could Shoot 40% Higher, Says Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Stock Could Shoot 40% Higher, Says Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-20 08:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/other-memes/tilray-stock-could-shoot-40-higher-says-wall-street><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street’s consensus on TLRY suggests that shares of the cannabis company have sizable upside potential. Wall Street Memes looks at the bullish case on Tilray stock.\nCanadian-based drug ...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/tilray-stock-could-shoot-40-higher-says-wall-street\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://www.thestreet.com/memestocks/other-memes/tilray-stock-could-shoot-40-higher-says-wall-street","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159389843","content_text":"Wall Street’s consensus on TLRY suggests that shares of the cannabis company have sizable upside potential. Wall Street Memes looks at the bullish case on Tilray stock.\nCanadian-based drug manufacturer Tilray is one of the most popular cannabis stocks across the online forums. Shares have sunk around 80% to $12 since spiking in early February, catching the attention of bargain hunters.\nFigure 1: Tilray products are displayed in Nanaimo.\nFollowing dismal performance in the past months, Wall Street sees opportunity. Could now be a good time to buy the stock near its 2021 lows?\nThe consensus rating on Tilray stock is a moderate buy with solid 40% upside potential. Based on the average of 11 reports published in the last 3 months, TLRY should be worth just short of $17.\nThe most bullish analyst is Jefferies’ Owen Bennett, who sees gain potential of 125% at his price target of $27. He expects Tilray to strike sizable deals in the US some time soon. The analyst also thinks that Tilray should buy cannabis assets to achieve the company’s ambitious sales target.\nOnly a bit less bullish is Bank of America’s analyst Heather Balsky. Shebelievesin 80% upside at a price target of $21.50. The acquisition of MedMen positions the company well in the US and provides distribution opportunities in Canada and Europe. The analyst stated:\n\n“We expect Tilray to pursue additional opportunities in the US with a focus on brands versus acquiring certain licenses. We view each incremental transaction in the US cannabis market as a positive catalyst.\"\n\nNot so bullish was the latest take from Piper Sandler. Analyst Michael Lavery reiterated his neutral position on TLRY stock and lowered his price target from $15 to $14.\nAccording to him, increased competition from low-price providers should weigh on Tilray. Still, despite his neutral stance, the analyst sees 19% upside on TLRY over the next year – not bad, considering how richly valued stocks in general have become in the past several months.\nThe least bullish analyst on record is CIBC John Zamparo, whoseta price target of $13.40 on TLRY two months ago. The analyst believes that forecasting the cannabis industry is very difficult – more so for Tilray, after its reverse-merger deal with Aphria earlier in 2021.\nWall Street Meme’s take\n“Regulation” is still the key word for cannabis stocks. Lack of positive news regarding legalization can lead to extended periods of softness in stock prices, which has been happening lately. However, Wall Street appears to see more upside than downside in the space.\nTilray faces the usual integration risks following the recent Aphria and MedMen deals. Still, this may be what it takes for the company to position itself ahead of the competition. As the cannabis industry matures, Tilray may emerge as a winner, and its stock could ride the upside.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":887709086,"gmtCreate":1632097031745,"gmtModify":1676530698886,"author":{"id":"3581562038507991","authorId":"3581562038507991","name":"卖女孩的小火柴v","avatar":"https://static.tigerbbs.com/ba918be4c84fbffa0546cae2b23bfbb7","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581562038507991","authorIdStr":"3581562038507991"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887709086","repostId":1159389843,"repostType":4,"repost":{"id":"1159389843","pubTimestamp":1632096090,"share":"https://ttm.financial/m/news/1159389843?lang=&edition=fundamental","pubTime":"2021-09-20 08:01","market":"us","language":"en","title":"Tilray Stock Could Shoot 40% Higher, Says Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1159389843","media":"TheStreet","summary":"Wall Street’s consensus on TLRY suggests that shares of the cannabis company have sizable upside pot","content":"<p>Wall Street’s consensus on TLRY suggests that shares of the cannabis company have sizable upside potential. Wall Street Memes looks at the bullish case on Tilray stock.</p>\n<p>Canadian-based drug manufacturer Tilray&nbsp;is one of the most popular cannabis stocks across the online forums. Shares have sunk around 80% to $12 since spiking in early February, catching the attention of bargain hunters.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3186cce4e6eba2601c4b1943a3d82a72\" tg-width=\"804\" tg-height=\"536\" width=\"100%\" height=\"auto\"><span>Figure 1: Tilray products are displayed in Nanaimo.</span></p>\n<p>Following dismal performance in the past months, Wall Street sees opportunity. Could now be a good time to buy the stock near its 2021 lows?</p>\n<p>The consensus rating on Tilray stock is a&nbsp;moderate buy&nbsp;with solid 40% upside potential. Based on the average of 11 reports published in the last 3 months, TLRY should be worth just short of $17.</p>\n<p>The most bullish analyst is&nbsp;<b>Jefferies</b>’ Owen Bennett, who sees gain potential of 125% at his price target of $27. He&nbsp;expects&nbsp;Tilray to strike sizable deals in the US some time soon. The analyst also thinks that Tilray should buy cannabis assets to achieve the company’s ambitious sales target.</p>\n<p>Only a bit less bullish is&nbsp;<b>Bank of America</b>’s analyst Heather Balsky. Shebelievesin 80% upside at a price target of $21.50. The acquisition of MedMen positions the company well in the US and provides distribution opportunities in Canada and Europe. The analyst stated:</p>\n<blockquote>\n <i>“We expect Tilray to pursue additional opportunities in the US with a focus on brands versus acquiring certain licenses. We view each incremental transaction in the US cannabis market as a positive catalyst.\"</i>\n</blockquote>\n<p>Not so bullish was the latest take from&nbsp;<b>Piper Sandler</b>. Analyst Michael Lavery reiterated his neutral position on TLRY stock and lowered his price target from $15 to $14.</p>\n<p>According&nbsp;to him, increased competition from low-price providers should weigh on Tilray. Still, despite his neutral stance, the analyst sees 19% upside on TLRY over the next year – not bad, considering how richly valued stocks in general have become in the past several months.</p>\n<p>The least bullish analyst on record is&nbsp;<b>CIBC</b>&nbsp;John Zamparo, whoseta price target of $13.40 on TLRY two months ago. The analyst believes that forecasting the cannabis industry is very difficult – more so for Tilray, after its reverse-merger deal with Aphria earlier in 2021.</p>\n<p><b>Wall Street Meme’s take</b></p>\n<p>“Regulation” is still the key word for cannabis stocks. Lack of positive news regarding legalization can lead to extended periods of softness in stock prices, which has been happening lately. However, Wall Street appears to see more upside than downside in the space.</p>\n<p>Tilray faces the usual integration risks following the recent Aphria and MedMen deals. Still, this may be what it takes for the company to position itself ahead of the competition. As the cannabis industry matures, Tilray may emerge as a winner, and its stock could ride the upside.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Stock Could Shoot 40% Higher, Says Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Stock Could Shoot 40% Higher, Says Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-20 08:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/other-memes/tilray-stock-could-shoot-40-higher-says-wall-street><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street’s consensus on TLRY suggests that shares of the cannabis company have sizable upside potential. Wall Street Memes looks at the bullish case on Tilray stock.\nCanadian-based drug ...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/tilray-stock-could-shoot-40-higher-says-wall-street\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://www.thestreet.com/memestocks/other-memes/tilray-stock-could-shoot-40-higher-says-wall-street","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159389843","content_text":"Wall Street’s consensus on TLRY suggests that shares of the cannabis company have sizable upside potential. Wall Street Memes looks at the bullish case on Tilray stock.\nCanadian-based drug manufacturer Tilray is one of the most popular cannabis stocks across the online forums. Shares have sunk around 80% to $12 since spiking in early February, catching the attention of bargain hunters.\nFigure 1: Tilray products are displayed in Nanaimo.\nFollowing dismal performance in the past months, Wall Street sees opportunity. Could now be a good time to buy the stock near its 2021 lows?\nThe consensus rating on Tilray stock is a moderate buy with solid 40% upside potential. Based on the average of 11 reports published in the last 3 months, TLRY should be worth just short of $17.\nThe most bullish analyst is Jefferies’ Owen Bennett, who sees gain potential of 125% at his price target of $27. He expects Tilray to strike sizable deals in the US some time soon. The analyst also thinks that Tilray should buy cannabis assets to achieve the company’s ambitious sales target.\nOnly a bit less bullish is Bank of America’s analyst Heather Balsky. Shebelievesin 80% upside at a price target of $21.50. The acquisition of MedMen positions the company well in the US and provides distribution opportunities in Canada and Europe. The analyst stated:\n\n“We expect Tilray to pursue additional opportunities in the US with a focus on brands versus acquiring certain licenses. We view each incremental transaction in the US cannabis market as a positive catalyst.\"\n\nNot so bullish was the latest take from Piper Sandler. Analyst Michael Lavery reiterated his neutral position on TLRY stock and lowered his price target from $15 to $14.\nAccording to him, increased competition from low-price providers should weigh on Tilray. Still, despite his neutral stance, the analyst sees 19% upside on TLRY over the next year – not bad, considering how richly valued stocks in general have become in the past several months.\nThe least bullish analyst on record is CIBC John Zamparo, whoseta price target of $13.40 on TLRY two months ago. The analyst believes that forecasting the cannabis industry is very difficult – more so for Tilray, after its reverse-merger deal with Aphria earlier in 2021.\nWall Street Meme’s take\n“Regulation” is still the key word for cannabis stocks. Lack of positive news regarding legalization can lead to extended periods of softness in stock prices, which has been happening lately. However, Wall Street appears to see more upside than downside in the space.\nTilray faces the usual integration risks following the recent Aphria and MedMen deals. Still, this may be what it takes for the company to position itself ahead of the competition. As the cannabis industry matures, Tilray may emerge as a winner, and its stock could ride the upside.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":887442134,"gmtCreate":1632096253028,"gmtModify":1676530698534,"author":{"id":"3563581390514944","authorId":"3563581390514944","name":"NRN","avatar":"https://static.tigerbbs.com/3561ad0f76bae7ec1e64062bc70f0207","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3563581390514944","authorIdStr":"3563581390514944"},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/887442134","repostId":1159389843,"repostType":4,"repost":{"id":"1159389843","pubTimestamp":1632096090,"share":"https://ttm.financial/m/news/1159389843?lang=&edition=fundamental","pubTime":"2021-09-20 08:01","market":"us","language":"en","title":"Tilray Stock Could Shoot 40% Higher, Says Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1159389843","media":"TheStreet","summary":"Wall Street’s consensus on TLRY suggests that shares of the cannabis company have sizable upside pot","content":"<p>Wall Street’s consensus on TLRY suggests that shares of the cannabis company have sizable upside potential. Wall Street Memes looks at the bullish case on Tilray stock.</p>\n<p>Canadian-based drug manufacturer Tilray&nbsp;is one of the most popular cannabis stocks across the online forums. Shares have sunk around 80% to $12 since spiking in early February, catching the attention of bargain hunters.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3186cce4e6eba2601c4b1943a3d82a72\" tg-width=\"804\" tg-height=\"536\" width=\"100%\" height=\"auto\"><span>Figure 1: Tilray products are displayed in Nanaimo.</span></p>\n<p>Following dismal performance in the past months, Wall Street sees opportunity. Could now be a good time to buy the stock near its 2021 lows?</p>\n<p>The consensus rating on Tilray stock is a&nbsp;moderate buy&nbsp;with solid 40% upside potential. Based on the average of 11 reports published in the last 3 months, TLRY should be worth just short of $17.</p>\n<p>The most bullish analyst is&nbsp;<b>Jefferies</b>’ Owen Bennett, who sees gain potential of 125% at his price target of $27. He&nbsp;expects&nbsp;Tilray to strike sizable deals in the US some time soon. The analyst also thinks that Tilray should buy cannabis assets to achieve the company’s ambitious sales target.</p>\n<p>Only a bit less bullish is&nbsp;<b>Bank of America</b>’s analyst Heather Balsky. Shebelievesin 80% upside at a price target of $21.50. The acquisition of MedMen positions the company well in the US and provides distribution opportunities in Canada and Europe. The analyst stated:</p>\n<blockquote>\n <i>“We expect Tilray to pursue additional opportunities in the US with a focus on brands versus acquiring certain licenses. We view each incremental transaction in the US cannabis market as a positive catalyst.\"</i>\n</blockquote>\n<p>Not so bullish was the latest take from&nbsp;<b>Piper Sandler</b>. Analyst Michael Lavery reiterated his neutral position on TLRY stock and lowered his price target from $15 to $14.</p>\n<p>According&nbsp;to him, increased competition from low-price providers should weigh on Tilray. Still, despite his neutral stance, the analyst sees 19% upside on TLRY over the next year – not bad, considering how richly valued stocks in general have become in the past several months.</p>\n<p>The least bullish analyst on record is&nbsp;<b>CIBC</b>&nbsp;John Zamparo, whoseta price target of $13.40 on TLRY two months ago. The analyst believes that forecasting the cannabis industry is very difficult – more so for Tilray, after its reverse-merger deal with Aphria earlier in 2021.</p>\n<p><b>Wall Street Meme’s take</b></p>\n<p>“Regulation” is still the key word for cannabis stocks. Lack of positive news regarding legalization can lead to extended periods of softness in stock prices, which has been happening lately. However, Wall Street appears to see more upside than downside in the space.</p>\n<p>Tilray faces the usual integration risks following the recent Aphria and MedMen deals. Still, this may be what it takes for the company to position itself ahead of the competition. As the cannabis industry matures, Tilray may emerge as a winner, and its stock could ride the upside.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Stock Could Shoot 40% Higher, Says Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Stock Could Shoot 40% Higher, Says Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-20 08:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/other-memes/tilray-stock-could-shoot-40-higher-says-wall-street><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street’s consensus on TLRY suggests that shares of the cannabis company have sizable upside potential. Wall Street Memes looks at the bullish case on Tilray stock.\nCanadian-based drug ...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/tilray-stock-could-shoot-40-higher-says-wall-street\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://www.thestreet.com/memestocks/other-memes/tilray-stock-could-shoot-40-higher-says-wall-street","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159389843","content_text":"Wall Street’s consensus on TLRY suggests that shares of the cannabis company have sizable upside potential. Wall Street Memes looks at the bullish case on Tilray stock.\nCanadian-based drug manufacturer Tilray is one of the most popular cannabis stocks across the online forums. Shares have sunk around 80% to $12 since spiking in early February, catching the attention of bargain hunters.\nFigure 1: Tilray products are displayed in Nanaimo.\nFollowing dismal performance in the past months, Wall Street sees opportunity. Could now be a good time to buy the stock near its 2021 lows?\nThe consensus rating on Tilray stock is a moderate buy with solid 40% upside potential. Based on the average of 11 reports published in the last 3 months, TLRY should be worth just short of $17.\nThe most bullish analyst is Jefferies’ Owen Bennett, who sees gain potential of 125% at his price target of $27. He expects Tilray to strike sizable deals in the US some time soon. The analyst also thinks that Tilray should buy cannabis assets to achieve the company’s ambitious sales target.\nOnly a bit less bullish is Bank of America’s analyst Heather Balsky. Shebelievesin 80% upside at a price target of $21.50. The acquisition of MedMen positions the company well in the US and provides distribution opportunities in Canada and Europe. The analyst stated:\n\n“We expect Tilray to pursue additional opportunities in the US with a focus on brands versus acquiring certain licenses. We view each incremental transaction in the US cannabis market as a positive catalyst.\"\n\nNot so bullish was the latest take from Piper Sandler. Analyst Michael Lavery reiterated his neutral position on TLRY stock and lowered his price target from $15 to $14.\nAccording to him, increased competition from low-price providers should weigh on Tilray. Still, despite his neutral stance, the analyst sees 19% upside on TLRY over the next year – not bad, considering how richly valued stocks in general have become in the past several months.\nThe least bullish analyst on record is CIBC John Zamparo, whoseta price target of $13.40 on TLRY two months ago. The analyst believes that forecasting the cannabis industry is very difficult – more so for Tilray, after its reverse-merger deal with Aphria earlier in 2021.\nWall Street Meme’s take\n“Regulation” is still the key word for cannabis stocks. Lack of positive news regarding legalization can lead to extended periods of softness in stock prices, which has been happening lately. However, Wall Street appears to see more upside than downside in the space.\nTilray faces the usual integration risks following the recent Aphria and MedMen deals. Still, this may be what it takes for the company to position itself ahead of the competition. As the cannabis industry matures, Tilray may emerge as a winner, and its stock could ride the upside.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5927238,"gmtCreate":1632096580365,"gmtModify":1663234129854,"authorId":3582453112692311,"author":{"id":3582453112692311,"idStr":"3582453112692311","authorId":3582453112692311,"name":"KBchan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":887442134,"type":1,"supId":0,"prevId":0,"content":"moon","text":"moon","html":"moon"},{"id":5927392,"gmtCreate":1632097024530,"gmtModify":1663234128354,"authorId":3581562038507991,"author":{"id":3581562038507991,"idStr":"3581562038507991","authorId":3581562038507991,"name":"卖女孩的小火柴v","avatar":"https://static.tigerbbs.com/ba918be4c84fbffa0546cae2b23bfbb7","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":887442134,"type":1,"supId":5927249,"prevId":0,"content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>"},{"id":5927249,"gmtCreate":1632096620561,"gmtModify":1634791891354,"authorId":3582186770863797,"author":{"id":3582186770863797,"idStr":"3582186770863797","authorId":3582186770863797,"name":"Pschoa","avatar":"https://static.tigerbbs.com/6048d8c3ccf7b9e4abd018d7a405e329","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":887442134,"type":1,"supId":0,"prevId":0,"content":"Hi","text":"Hi","html":"Hi"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":78,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}